
BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Levy, Ronald, MD	POSITION TITLE Professor of Medicine		
eRA COMMONS USER NAME (credential, e.g., agency login) LEVY.RONALD			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Harvard University, Boston, Massachusetts	AB	1963	Biochemistry
Stanford University, Stanford, California	MD	1968	Medicine

Positions and Employment

1968-1969	Internship Internal Medicine, Massachusetts General Hospital, Boston, MA
1969-1970	Residency Internal Medicine, Massachusetts General Hospital, Boston, MA
1970-1972	Clin. Assoc., Immunology Branch, National Cancer Institute, Bethesda, MD
1972-1973	Fellow, Department of Medicine, Division of Oncology, Stanford University School of Medicine
1973-1975	Fellow of the Helen Hay Whitney Foundation, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel
1975-1981	Assistant Professor of Medicine, Division of Oncology, Stanford University School of Medicine
1981-1987	Associate Professor of Medicine, Division of Oncology, Stanford University School of Medicine
1987-Present	Professor of Medicine, Division of Oncology, Stanford University School of Medicine
1987-Present	Robert K. Summy and Helen K. Summy Professor, Stanford University School of Medicine
1993-Present	Chief of the Division of Oncology, Stanford University School of Medicine

Other Experience and Professional Memberships

2001-2004	General Motors Cancer Research Foundation Awards Assembly
2003-2007	Member Research Council, American Cancer Society
2001-2004	G&P Charitable Foundation Award
2002-2004	The V Foundation Award
1994-Present	Scientific Advisory Board, Fred Hutchinson Cancer Research Center
2001-Present	Margaret Early Trust Grant Committee
2002-Present	Damon Runyon Clinical Investigators Award Committee
2002-Present	Lymphoma Research Foundation Grant Committee
2002-Present	Board of Directors, Damon Runyon Cancer Research Fund
2007-Present	Chairman, Rachleff Research Award, Damon Runyon Research Fund

Honors

1977	Investigator, Howard Hughes Medical Institute
1979	Member, American Society of Clinical Investigation
1982	Armand Hammer Award for Cancer Research
1983	Ciba-Geigy Drew Award in Biomedical Research
1987	Member, Association of American Physicians
1987	American Cancer Society Clinical Research Professorship
1989	Joseph Steiner Prize
1997	Joseph H. Burchenal, Clin. Cancer Res. Award, American Assoc. for Cancer Research
1999	Karnofsky Award, American Society of Clinical Oncology
1999	Charles Kettering Prize, General Motors Cancer Research Foundation

Program Director/Principal Investigator (Last, First, Middle): Levy, Ronald

2000 C. Chester Stock Award, Memorial Sloan-Kettering Cancer Center
2000 Medal of Honor, American Cancer Society
2000 Key to the Cure Award, Cure For Lymphoma Foundation
2001 Evelyn Hoffman Memorial Award, Lymphoma Research Foundation of America
2003 Jeffrey A. Gottlieb Memorial Award, M.D. Anderson Cancer Center
2004 Damashek Prize, American Society of Hematology
2007 Member, Institute of Medicine of the National Academies
2007 di Villers International Achievement Award, Leukemia and Lymphoma Society
2008 Member, National Academy of Sciences
2009 King Faisal International Prize, The King Faisal Foundation

Publications (recent publications out of 250)

Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, Natkunam Y, Briones J, Advani R, Connors JM, Byrne GE, **Levy R**, Gascoyne RD, Lossos IS. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. *Blood*. 2008 Jun 15;111(12):5509-14.

McCormick AA, Reddy S, Reinl SJ, Cameron TI, Czerwinski DK, Vojdani F, Hanley KM, Garger SJ, White EL, Novak J, Barrett J, Holtz RB, Tusé D, **Levy R**. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. *Proc Natl Acad Sci U S A*. 2008 Jul 22;105(29):10131-6

Brody JD, Goldstein MJ, Czerwinski DK, **Levy R**. Immunotransplant preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. *Blood*. 2009 Jan 1;113(1):85-94

Ai WZ, Hou JZ, Zeiser R, Czerwinski D, Negrin RS, Levy R. Follicular lymphoma B cells induce the conversion of conventional CD4(+) T cells to T-regulatory cells. *Int J Cancer*. 2008 Sep 23;124(1):239-244.

Roch H., Levy R. T cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. *Blood*, 9 April 2009, Vol. 113, No. 15, pp. 3546-3552.

Timmerman J, Vose J, Czerwinski D., Weng Wen-Kai, Ingolia D, Mayo, M, Denny D, **Levy R.**, Tumor-Specific Recombinant Idiotype Immunization After Chemotherapy as Initial Treatment for Follicular Non-Hodgkin's Lymphoma. *Leuk Lymphoma*. 2009 Jan; 50(1):1-2

Houot R, **Levy R**. Idiotype vaccination for lymphoma: moving towards optimisation. *Leuk Lymphoma*. 2009 Jan;50(1):1-2

Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Gil EC, **Levy R**, Lossos IS, Natkunam Y. The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. *Am J Clin Pathol*. 2009 Feb;131(2):264-78

Weiyun Z. Ai, Robert Tibshirani, Behnaz Taidi, Debra Czerwinski, and Ronald Levy, Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma *Blood*, Apr 2009; doi:10.1182/blood-2009-01-201988 [Epub ahead of print]

Weng WK, Levy R. Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab *Leuk Lymphoma*. 2009 May;50(5):723-7.

Houot R, Levy R. Vaccines for lymphomas: idiotype vaccines and beyond, *Blood Rev*. 2009 May;23(3):137-42

Weng WK, Levy R. Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. *Leuk Lymphoma*. 2009 May;50(5):723-7.

Alizadeh AA, Gentles AJ, Lossos IS, Levy R. Molecular outcome prediction in diffuse large-B-cell lymphoma. N Engl J Med. 2009 Jun 25;360(26):2794-5.

Related Research Support

Current

P01 CA34233 (R. Levy)

07/17/06-03/31/11

NIH/NCI

Clinical and Laboratory Studies of Malignant Lymphoma

Project 1 Core A

The overall theme of the program is to understand the signals that cause and that regulate malignant lymphomas. Our focus is on the immune system, since these tumors are derived from the cells of the immune system. We plan to extend findings made in our current program and to take advantage of new technology that we have helped develop. To enable our work we have access to large numbers of patients with lymphoma, and we have built a tumor tissue bank and clinical database extending over several decades.

LLS 7107-06 (R. Levy)

10/01/05-09/30/10

Leukemia and Lymphoma Society

Immunological Signals and the Control of Lymphoma

Project Leader – Project 2, Lymphoma Genomic Signatures

Lymphoma is the cancer of the immune system. We have learned that cells of the normal immune system respond to the environment and to each other through cell surface receptors that transmit signals into the cell to activate specific patterns of gene expression. In Project 2, We will apply novel genomic technologies and new bioinformatics methodologies to learn how patients with lymphoma can be subdivided according to risk so that action plans can be customized for each patient.

P30 CA124435 (B. Mitchell)

06/04/07-05/31/10

NIH/NCI

Cancer Center Support Grant

Lymphoma Program (R. Levy, Program Director)

Stanford University has been awarded three years of funding and designation as Stanford Cancer Center while building multidisciplinary programs in order to apply for designation as a Comprehensive Cancer Center.

P01 CA049605 (Negrin)

04/05/07-02/28/12

NIH/NCI

Bone Marrow Grafting for Leukemia and Lymphoma

Project 2: Autografting for Lymphoma (Horning Project Co-Leader/R. Levy Project Co-Leader)

This project involves a number of innovative clinical studies for patients with recurrent Hodgkin's or non-Hodgkin's lymphoma, including the incorporation of new antineoplastic agents and targeted radioimmunotherapy markers.

P20 CA112973 (S. Plevritis)

09/30/04-08/31/09

NIH/NCI

Computational Modeling of Cancer Biology

The major goal of this project is to develop a multi-disciplinary research program in systems biology of cancer. Initial pilot projects will focus on computational models of the genetic regulatory networks and signaling pathways that identify the molecular mechanisms underlying the transformation from low grade to high grade lymphoma.

Program Director/Principal Investigator (Last, First, Middle): Levy, Ronald
R01 CA122105 (Lossos)
University of Miami (NIH prime)
Prognostic Models in Diffuse Large B-Cell Lymphoma

09/24/07 – 07/31/11

We will identify genes associated with either good or bad outcome in DLBCL patients treated with R-CHOP, will construct robust predictive models based on RNA extracted from paraffin specimens as well on immunohistochemistry and will examine the predictive power of new biomarkers associated with the anti-tumor effects of rituximab. The acquisition of fixed tissue as a component of this uniformly treated prospective study will also afford future studies with this informative dataset.

American Cancer Society
CRP 87-009-21
Immunobiology of Human Lymphoid Malignancy

07/1/02-12/31/11

Frank and Else Schilling – American Cancer Society, Clinical Research Professorship. This professorship is awarded in recognition of Dr. Ronald Levy's scientific accomplishments. It does not support a specific research project.

Alliance for Cancer Gene Therapy (ACGT)

04/01/08-03/31/12

Phase II Study of a CD154-Gene Transfer Vaccine for Mantle Cell Lymphoma After Autologous Peripheral Blood Stem Cell Transplantation

Leukemia and Lymphoma Society (Knox)
Strategic Design of Novel Radiation and
Immunotherapeutic Combinations

10/1/08 - 9/30/11

The major goals of this project are to use A20 lymphoma cells in vitro and syngeneic murine A20 lymphomas in vivo to determine how best to use radiation combined with blockade of radiation-induced inhibitory receptors in immune cells as a lymphoma tumor vaccine strategy.

Leukemia and Lymphoma Society (Blau)
Bioengineered Niches to Control Human
Follicular Lymphoma Cells

10/01/08-09/30/11

Leukemia and Lymphoma Society (Stroeber)
Treatment of Lymphoma with Tumor Immune
Marrow Transplants

10/01/08-09/30/11

Completed

Lymphoma Research Foundation (R. Levy)

06/01/07-05/31/09

BCR Signal Transduction in Mantle Cell Lymphoma Patients Receiving a Syk Kinase Inhibitor

R37 CA33399 (R. Levy)
NIH/NCI

08/29/03-05/31/08

Anti-Idiotypic Therapy of Human B-Cell Malignancy

This is a continuation of therapeutic trials of monoclonal anti-idiotypic antibodies for patients with follicular lymphoma. Clinical trials of active immunization of patients with their own idiotype. The process of mutation in immunoglobulin genes in human B Cell tumors is studied. The interaction between the B Cell tumor and the human host is studied, and an animal model of therapeutic use of anti-idiotypic proteins is developed.